NEUROCRINE BIOSCIENCES INC R&D Expense

Quick Answer

NEUROCRINE BIOSCIENCES INC reported R&D Expense of $160.52 million for fiscal year 2018.

NEUROCRINE BIOSCIENCES INC R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2018 $160.52M +31.8%
2017 $121.83M +29.2%
2016 $94.29M +15.7%
2015 $81.49M +75.5%
2014 $46.42M +18.3%
2013 $39.25M +5.6%
2012 $37.16M +20.1%
2011 $30.95M -0.6%
2010 $31.15M -7.6%
2009 $33.72M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
March 31, 2021 $73.20M +25.6% +25.6%
March 31, 2020 $58.30M +54.8% -5.5%
June 30, 2019 $61.69M +66.8% +63.8%
March 31, 2019 $37.65M -23.1% +6.1%
September 30, 2018 $35.48M +58.0% -4.1%
June 30, 2018 $36.99M +69.1% -24.4%
March 31, 2018 $48.95M -5.7% +117.9%
September 30, 2017 $22.46M +7.3% +2.7%
  • NEUROCRINE BIOSCIENCES INC showed an increase of +31.8% in R&D Expense compared to the prior fiscal year.
  • Over the 2009–2018 period, NEUROCRINE BIOSCIENCES INC’s r&d expense has grown by 376.0% (from $33.72 million to $160.52 million).
  • The most recent figure is from NEUROCRINE BIOSCIENCES INC’s fiscal year 2018 report (Form 10-K), filed with the SEC on February 8, 2019.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment